Fibrosis
The Disease
Fibrosis is the replacement of functional tissue with fibrous connective tissue. This replacement leads to organ disfunction, organ failure and finally can lead to death. Fibrosis can affect all tissues in the body, with underlying aetiologies and mechanisms being rather organ specific.
There are only two approved anti-fibrotic therapies (Pirfenidone and Nintedanib) and both are licenced exclusively for the treatment of patients with mild-moderate Idiopathic Pulmonary Fibrosis (IPF)]. There is therefore an urgent unmet need to develop new anti-fibrotic therapies for use in other fibrotic diseases.
Evaluation Platforms
Mice can be treated either prophylactically -at disease onset- or therapeutically –at established pathology- with protocols standardized for the evaluation of a variety of therapeutics. Disease progress and severity are assessed regularly using validated readouts with standardized procedures.
Read-Out Parameters
Body weight changes
Histopathological evaluation of lung sections
Serum SP-D levels
Fibrosis markers expression levels
Competitive Advantage
Biomedcode has standardised bleomycin induction, treatment and evaluation protocols, allowing the validation of the preclinical platform with nintedanib.
Precision cut lung slices are the basis for the ex vivo preclinical evaluation platform of the efficacy of antifibrotic drugs.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
